Journal of Endocrinological Investigation

, Volume 25, Issue 9, pp 773–778 | Cite as

Somatostatin analogs in the treatment of medullary thyroid carcinoma

Original Article


The medical therapy for advanced or metastatic medullary thyroid carcinoma has not been fully established. Somatostatin analogs have been used with variable success in the therapy of a few patients with medullary thyroid carcinoma. In the present study, we evaluated the effects of somatostatin analog therapy on calcitonin (ct) and carcinoembryonic antigen in patients with advanced medullary thyroid carcinoma. Five patients (2 men and 3 women, aged 35-57 yr) with post-operative recurrent medullary thyroid carcinoma received somatostatin analog therapy for 12 weeks. All had been previously treated with total thyroidectomy and lymphadenectomy. Four of them showed positive uptake in 111In-pentetreotide scanning. One patient was treated with sc octreotide (100 μg/8 h), 3 patients received im slow release lanreotide (30 mg/14 days), and a further one received im octreotide LAR (30 mg/28 days). Serum samples for ct and carcinoembryonic antigen were obtained at 0, 1, 2, 4, 8 and 12 weeks of therapy. Therapy was well-tolerated in general, with minimal side-effects. One patient died after the first month of therapy because of advanced disease. Another patient showed normalization of his ct and carcinoembryonic antigen concentrations at the second week of therapy, maintaining elevated values thereafter. No clinically relevant changes in serum concentrations of ct and carcinoembryonic antigen were observed in the rest of the patients. One patient with positive 111In-pentetreotide scan, showed no uptake after somatostatin analog therapy. No significant decrease in the size of metastases was evident in the remaining patients. In conclusion, therapy with different formulations of octreotide and lanreotide does not seem to modify serum concentrations of ct and carcinoembryonic antigen in patients with recurrent medullary thyroid carcinoma.

Key words

Octreotide lanreotide medullary thyroid carcinoma 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ball D.W., Baylin S.B., de Bustros A.C. Medullary thyroid carcinoma. In: Braverman L.E. & Utiger R.D. (Eds.), Werner and Ingbar’s The Thyroid, 7th ed. Lippincott-Raven, Philadelphia, 1996, p. 946–960.Google Scholar
  2. 2.
    Vitale G., Garaglia M., Ciccarelli A., et al. Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer 2001, 91: 1797–1808.PubMedCrossRefGoogle Scholar
  3. 3.
    Mato E., Matías-Guiu X., Chico A., et al. Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 1998, 83: 2417–2420.PubMedGoogle Scholar
  4. 4.
    Lamberts S.W.J., Van der Lely A.J., De Herder W.W., Hofland L.J. Octreotide. N. Engl. J. Med. 1996, 334: 246–254.PubMedCrossRefGoogle Scholar
  5. 5.
    Modigliani E., Guliana J.M., Maroni M., et al. Effets de l’administration sous cutanée de la sandostatine (SMS 201.995) en sous cutané dans 18 cas de cancer médullaire du corps thyroïde. Ann. Endocrinol. (Paris) 1989, 50: 483–488.Google Scholar
  6. 6.
    Guliana J.M., Guillausseau P.J., Caron J., Siame-Mourot C., Calmettes C., Modigliani E. Effects of the short-term subcutaneous administration of SMS 201-995 on calcitonin plasma levels in patients suffering from medullary thyroid carcinoma. Horm. Metab. Res. 1989, 21: 584–586.PubMedCrossRefGoogle Scholar
  7. 7.
    Libroia A., Verga U., Di Sacco G., Piolini M., Muratori F. Use of somatostatin analog SMS 201-995 in medullary thyroid carcinoma. Henry Ford Hosp. Med. J. 1989, 37: 151–153.PubMedGoogle Scholar
  8. 8.
    Libroia A., Di Sacco G., Verga U., Piolini M., Muratori F. Effect of the chronic administration of Sandostatin in two patients affected by medullary thyroid carcinoma responders to the acute test (abstract). J. Endocrinol. Invest. 1990, 13: 222.Google Scholar
  9. 9.
    Lupoli G., Cascone E., Arlotta F., et al. Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon α-2β and octreotide. Cancer 1996, 78: 1114–1118.PubMedCrossRefGoogle Scholar
  10. 10.
    Vitale G., Tagliaferri P., Caraglia M., et al. Slow release lanreotide in combination with interferon-α2β in the treatment of symptomatic advanced medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 2000, 85: 983–988.PubMedGoogle Scholar
  11. 11.
    Geelhoed G.W., Bass B.L., Mertz S.L., Becker K.L. Somatostatin analog: effects on hypergastrinemia and hypercalcitoninemia. Surgery 1986, 100: 962–970.PubMedGoogle Scholar
  12. 12.
    Schrezenmeir J., Plewe G., Stürmer W., et al. Treatment of APUDomas with the long-acting somatostatin analogue SMS 201–995: Investigations of therapeutic use and digestive side effects. Scand. J. Gastroenterol. 1986, 21 (119): 223–227.CrossRefGoogle Scholar
  13. 13.
    Berkelhammer C.H., Rosenberg I.H., Fedorak R.N., O’Dorisio T.M. Inefficacy of somatostatin analogue SMS 201-995 in reducing severe diarrhoea in a patient with medullary thyroid carcinoma (abstract 246). Can. J. Physiol. Pharmacol. 1986, 64: 67.Google Scholar
  14. 14.
    Ahlman H., Tisell L.E. The use of long-acting somatostatin analogue in the treatment of advanced endocrine malignancies with gastrointestinal symptoms. Scand. J. Gastroenterol. 1987, 22: 938–942.PubMedCrossRefGoogle Scholar
  15. 15.
    Jerkins T.W., Sacks H.S., O’Dorisio T.M., Tuttle S., Solomon S.S. Medullary carcinoma of the thyroid, pancreatic nesidioblastosis and microadenosis, and pancreatic polypeptide hypersecretion: A new association and clinical and hormonal responses to long-acting somatostatin analog SMS 201–995. J. Clin. Endocrinol. Metab. 1987, 64: 1313–1319.PubMedCrossRefGoogle Scholar
  16. 16.
    Keeling C.A., Basso L.V. Iodine-131 MIBG uptake in metastatic medullary carcinoma of the thyroid. A patient treated with somatostatin. Clin. Nucl. Med. 1988, 13: 260–263.PubMedCrossRefGoogle Scholar
  17. 17.
    Sagman U., Fine S. Sandostatin in the treatment of advanced malignancies. In: Sandostatin in the Treatment of GEP Endocrine Tumours. Springer Verlag, Berlin Heidelberg, 1989, p. 83–87.CrossRefGoogle Scholar
  18. 18.
    Somlo G., Akman S.A., Doroshow J.H., et al. Treatment of neuroendocrine tumors with a somatostatin analogue (Sandostatin™) (abstract 378). Proc. Am. Soc. Clin. Oncol. 1990, 9: 97.Google Scholar
  19. 19.
    Mahler C., Verhelst J., De Longueville M., Harris A. Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide. Clin. Endocrinol. (Oxf.) 1990, 33: 261–269.CrossRefGoogle Scholar
  20. 20.
    Fugazzola L., Pacini F., Elisei R. Chronic somatostatin therapy is not effective in medullary thyroid cancer (abstract). J. Endocrinol. Invest. 1991, 14: 22.Google Scholar
  21. 21.
    Modigliani E., Cohen R., Joannidis S., et al. Results of long-term continuous subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma. Clin. Endocrinol. (Oxf.) 1992, 36: 183–186.CrossRefGoogle Scholar
  22. 22.
    Smid W.M., Dullaart R.P.F. Octreotide for medullary thyroid carcinoma associated diarrhoea. Neth. J. Med. 1992, 40: 240–243.PubMedGoogle Scholar
  23. 23.
    Kvols L.K., Reubi J.C., Horisberger U., Moertel C.G., Rubin J., Charboneau J.W. The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide. Yale J. Biol. Med. 1992, 65: 505–518.PubMedCentralPubMedGoogle Scholar
  24. 24.
    Frank-Raue K., Ziegler R., Raue F. The use of octreotide in the treatment of medullary thyroid carcinoma. Horm. Metab. Res. 1993, Suppl. (27): 44–47.Google Scholar
  25. 25.
    Frank-Raue K., Raue F., Ziegler R. Therapy of metastatic medullary thyroid gland carcinoma with the somatostatin analog octreotide. Med. Klin. 1995, 90: 63–66.Google Scholar
  26. 26.
    Ronga G., Salerno G., Procaccini E., et al. 111In-octreotide scintigraphy in metastatic medullary thyroid carcinoma before and after octreotide therapy: in vivo evidence of the possible down-regulation of somatostatin receptors. Q. J. Nucl. Med. 1995, 39: 134–136.PubMedGoogle Scholar
  27. 27.
    Sanabria C., Aguirre M., Domínguez-Gadea L. Utilidad del análogo de somatostatina octreotida en el tratamiento y seguimiento gammagráfico de un carcinoma medular de tiroides (abstract). Endocrinología 1995, 42: 28.Google Scholar
  28. 28.
    Di Bartolomeo M., Bajetta E., Buzzoni R., et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. Cancer 1996, 77: 402–408.PubMedCrossRefGoogle Scholar
  29. 29.
    Modigliani E., Chayvialle J.A., Cohen R., et al. Effect of a somatostatin analog (SMS 201-995) in perfusion on basal and pentagastrin-stimulated calcitonin levels in medullary thyroid carcinoma. Horm. Metab. Res. 1988, 20: 773–775.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2002

Authors and Affiliations

  1. 1.Department of EndocrinologyHospital La PazMadridSpain
  2. 2.Department of EndocrinologyHospital General de SegoviaSegoviaSpain

Personalised recommendations